Bmab-1800

N/A

Report date: 2026/05/14 20:00:28

Base Information

Drug NameBmab-1800
Drug Alias NamePembrolizumab biosimilar (Biocon Biologics)Bmab1800Bmab-1800
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBiocon Biologics UK Plc
China Registration ClassN/A

Develop Information

Active CompaniesBiocon Biologics UK Plc
Inactive CompaniesN/A
Active IndicationsMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A